Cancer Drug Access and Innovation Under the Inflation Reduction Act—A Balancing Act
This Viewpoint explores whether the Inflation Reduction Act’s provisions and price negotiations could affect investment in trials of new oncology therapies or indications.
Authors
- Frank David (ORCID: https://orcid.org/0000-0002-8025-4427)
- Stacie B. Dusetzina (ORCID: https://orcid.org/0000-0002-3907-9196)
Institutions
- Tufts University (US)
- Vanderbilt University (US)
- Vanderbilt Health (US)
- Vanderbilt-Ingram Cancer Center
Publication Details
- Journal
- JAMA Oncology
- Published
- 2024-10-24
- DOI
- https://doi.org/10.1001/jamaoncol.2024.4745
- Citations
- 5
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 5.65